Physician profile
James H Marshall
NPI 1013093566
$2,685.15
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $1,337 · 2021: $11.61 · 2023: $29.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $667.38 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $294.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $255.06 | 2019-2020 | |
| Pfizer INC. | $225.81 | 2019-2020 | |
| Allergan, INC. | $218.39 | 2019-2020 | |
| Amarin Pharma, INC. | $139.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $124.39 | 2019-2020 | |
| Lilly USA, LLC | $118.16 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.85 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $37.62 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $29.54 | 2023 | |
| Sanofi-Aventis U.S. LLC | $23.24 | 2020 | |
| Amgen INC. | $21.84 | 2019 | |
| Glaxosmithkline, LLC. | $17.87 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $17.33 | 2020 | |
| Grifols USA, LLC | $17.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.07 | 2019 | |
| Genentech USA, INC. | $13.98 | 2020 | |
| Aytu Biopharma, INC. | $13.29 | 2019 | |
| Abbvie INC. | $11.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.